Document Detail


Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
MedLine Citation:
PMID:  12860776     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) have gained wide acceptance in the treatment of mental disorders in pregnant women, but there seems to be an increased risk for neonatal adaptation problems after exposure to SSRIs in late pregnancy. We aimed to investigate the perinatal sequelae of infants exposed to SSRIs during their fetal life and the relationship of these symptoms to the cord blood monoamine and prolactin concentrations. METHODS: We conducted a prospective, controlled, follow-up study with 20 mothers taking 20 to 40 mg/d of either citalopram or fluoxetine for depression (n = 10) or panic disorder (n = 10) and their infants and 20 matched controls not receiving psychotropic medication for confounding obstetric characteristics. Maternal cord blood and infant citalopram, fluoxetine, and norfluoxetine, cord blood monoamine and metabolite, and prolactin concentrations were measured. The newborns underwent standard clinical examination and specific assessment of serotonergic symptoms during the first 4 days of life and at the ages of 2 weeks and 2 months. RESULTS: There was a statistically significant (P =.008, V = 15, n = 20 for both groups), 4-fold difference in the serotonergic symptom score during the first 4 days of life between the SSRI group and the control group. The SSRI-exposed infants had significantly lower cord blood 5-hydroxyindoleacetic acid (5-HIAA) concentrations (P =.02, t31 = 2.57) compared with the control group. A significant inverse correlation (rs = -0.66, P =.007, n = 15) was seen between the serotonergic symptom score and the umbilical vein 5-HIAA concentrations in the SSRI-exposed but not the control infants. CONCLUSIONS: Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Authors:
Kari Laine; Tuija Heikkinen; Ulla Ekblad; Pentti Kero
Related Documents :
6673606 - Plain roentgenography in the evaluation of unilateral vocal cord mobility.
8910656 - Lack of association between levels of transplacentally acquired plasmodium falciparum-s...
1733586 - Association between magnesium, calcium, phosphorus, copper, and zinc in umbilical cord ...
16607926 - The role of cord blood igf-i levels in preterm osteopenia.
18378236 - Sex differences and effects of neonatal aromatase inhibition on masculine and feminine ...
11879866 - Congenital rubella syndrome: a risk in immigrant populations.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of general psychiatry     Volume:  60     ISSN:  0003-990X     ISO Abbreviation:  Arch. Gen. Psychiatry     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-07-15     Completed Date:  2003-09-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372435     Medline TA:  Arch Gen Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  720-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Pharmacology and Clinical Pharmacology, University of Turku and Turku University Central Hospital, Turku, Finland. karlai@utu.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Depressive Disorder / blood,  drug therapy
Female
Fetal Blood / chemistry*
Humans
Hydroxyindoleacetic Acid / blood*
Infant, Newborn
Male
Maternal Exposure
Maternal-Fetal Exchange*
Mental Disorders / blood,  drug therapy*
Panic Disorder / blood,  drug therapy
Pregnancy
Pregnancy Complications / blood,  drug therapy*
Prolactin / blood*
Serotonin Syndrome / blood,  chemically induced*,  diagnosis
Serotonin Uptake Inhibitors / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Serotonin Uptake Inhibitors; 54-16-0/Hydroxyindoleacetic Acid; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-...
Next Document:  Neural response to alcohol stimuli in adolescents with alcohol use disorder.